Antibody Discovery News and Research

RSS

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has entered into a research and license option agreement regarding its ICT-69 antibody with Roche Group (SWX: ROG.VX; RO.S, OTCQX: RHHBY), one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics.

10 Sep 2009

Two new antibodies for targeting HIV virus discovered

Researchers at and associated with the International AIDS Vaccine Initiative (IAVI), at The Scripps Research Institute, and at the biotechnology companies Theraclone Sciences and Monogram Biosciences have discovered two powerful new antibodies to HIV that reveal what may be an Achilles heel on the virus. They published their work in Science this week.

3 Sep 2009

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Oxford BioTherapeutics (OBT) today announced a strategic alliance with GlaxoSmithKline to discover, develop and commercialise novel, therapeutic antibodies for the treatment of primary, metastatic and recurring forms of cancer.

18 May 2009

Xencor and CSL Limited establish antibody optimization collaboration

Xencor, Inc., an antibody discovery and development company, announced today that it has entered into an antibody optimization collaboration with CSL, Ltd. The collaboration will provide CSL with access to Xencor's XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

23 Feb 2009

Vaccinex antibody licensed to GlaxoSmithKline

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

18 Feb 2008

Morphotek announces agreement for development of antibodies to treat prostate cancer

Morphotek, Inc., a subsidiary of Eisai Co., Ltd., has announced that it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.

10 Jan 2008

Antibody Discovery News and Research

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

Two new antibodies for targeting HIV virus discovered

Oxford BioTherapeutics and GSK form alliance to develop cancer therapeutic antibodies

Xencor and CSL Limited establish antibody optimization collaboration

Vaccinex antibody licensed to GlaxoSmithKline

Morphotek announces agreement for development of antibodies to treat prostate cancer

Vaccinex receives new European patent for antibody discovery technology

Morphotek issued new U.S patent for method to enhance the affinity of monoclonal antibodies

Pfizer acquires antibody discovery company Bioren

Vaccinex and Biocon to co-develop at least four therapeutic antibody products

Immunology eBook

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Natural products: the next frontier in drug discovery

Latest News